187 related articles for article (PubMed ID: 23588815)
21. PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.
Petrella BL; Brinckerhoff CE
Cancer Biol Ther; 2009 Jul; 8(14):1389-401. PubMed ID: 19483472
[TBL] [Abstract][Full Text] [Related]
22. Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness.
He X; Wang J; Messing EM; Wu G
Oncogene; 2011 Feb; 30(5):535-47. PubMed ID: 20871634
[TBL] [Abstract][Full Text] [Related]
23. NADPH oxidase NOX4 supports renal tumorigenesis by promoting the expression and nuclear accumulation of HIF2α.
Gregg JL; Turner RM; Chang G; Joshi D; Zhan Y; Chen L; Maranchie JK
Cancer Res; 2014 Jul; 74(13):3501-3511. PubMed ID: 24755467
[TBL] [Abstract][Full Text] [Related]
24. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
[TBL] [Abstract][Full Text] [Related]
25. Pleiotrophin suppression of receptor protein tyrosine phosphatase-β/ζ maintains the self-renewal competence of fetal human oligodendrocyte progenitor cells.
McClain CR; Sim FJ; Goldman SA
J Neurosci; 2012 Oct; 32(43):15066-75. PubMed ID: 23100427
[TBL] [Abstract][Full Text] [Related]
26. Nuclear E-cadherin and VHL immunoreactivity are prognostic indicators of clear-cell renal cell carcinoma.
Gervais ML; Henry PC; Saravanan A; Burry TN; Gallie BL; Jewett MA; Hill RP; Evans AJ; Ohh M
Lab Invest; 2007 Dec; 87(12):1252-64. PubMed ID: 17906660
[TBL] [Abstract][Full Text] [Related]
27. Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.
Trotta AM; Santagata S; Zanotta S; D'Alterio C; Napolitano M; Rea G; Camerlingo R; Esposito F; Lamantia E; Anniciello A; Botti G; Longo N; Botti G; Pignata S; Perdonà S; Scala S
J Exp Clin Cancer Res; 2018 Dec; 37(1):297. PubMed ID: 30514329
[TBL] [Abstract][Full Text] [Related]
28. von Hippel-Lindau mutants in renal cell carcinoma are regulated by increased expression of RSUME.
Tedesco L; Elguero B; Pacin DG; Senin S; Pollak C; Garcia Marchiñena PA; Jurado AM; Isola M; Labanca MJ; Palazzo M; Yankilevich P; Fuertes M; Arzt E
Cell Death Dis; 2019 Mar; 10(4):266. PubMed ID: 30890701
[TBL] [Abstract][Full Text] [Related]
29. Synergistic signaling of tumor cell invasiveness by hepatocyte growth factor and hypoxia.
Lee YH; Morrison BL; Bottaro DP
J Biol Chem; 2014 Jul; 289(30):20448-61. PubMed ID: 24914205
[TBL] [Abstract][Full Text] [Related]
30. A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy.
Turcotte S; Chan DA; Sutphin PD; Hay MP; Denny WA; Giaccia AJ
Cancer Cell; 2008 Jul; 14(1):90-102. PubMed ID: 18598947
[TBL] [Abstract][Full Text] [Related]
31. The emerging role of nuclear factor kappa B in renal cell carcinoma.
Morais C; Gobe G; Johnson DW; Healy H
Int J Biochem Cell Biol; 2011 Nov; 43(11):1537-49. PubMed ID: 21854869
[TBL] [Abstract][Full Text] [Related]
32. Candidate tumor suppressor and pVHL partner Jade-1 binds and inhibits AKT in renal cell carcinoma.
Zeng L; Bai M; Mittal AK; El-Jouni W; Zhou J; Cohen DM; Zhou MI; Cohen HT
Cancer Res; 2013 Sep; 73(17):5371-80. PubMed ID: 23824745
[TBL] [Abstract][Full Text] [Related]
33. von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms.
Calzada MJ; Esteban MA; Feijoo-Cuaresma M; Castellanos MC; Naranjo-Suárez S; Temes E; Méndez F; Yánez-Mo M; Ohh M; Landázuri MO
Cancer Res; 2006 Feb; 66(3):1553-60. PubMed ID: 16452212
[TBL] [Abstract][Full Text] [Related]
34. 2'-hydroxyflavanone inhibits proliferation, tumor vascularization and promotes normal differentiation in VHL-mutant renal cell carcinoma.
Nagaprashantha LD; Vatsyayan R; Singhal J; Lelsani P; Prokai L; Awasthi S; Singhal SS
Carcinogenesis; 2011 Apr; 32(4):568-75. PubMed ID: 21304051
[TBL] [Abstract][Full Text] [Related]
35. VHL enhances 9-cis-retinoic acid treatment by down-regulating retinoid X receptor α in renal cell carcinomas.
Wang F; Wang LS; Gao YH; Yao XD
Biochem Biophys Res Commun; 2020 Mar; 523(2):535-541. PubMed ID: 31928714
[TBL] [Abstract][Full Text] [Related]
36. Small activating RNA induced expression of VHL gene in renal cell carcinoma.
Kang MR; Park KH; Lee CW; Lee MY; Han SB; Li LC; Kang JS
Int J Biochem Cell Biol; 2018 Apr; 97():36-42. PubMed ID: 29425832
[TBL] [Abstract][Full Text] [Related]
37. von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids.
Lieubeau-Teillet B; Rak J; Jothy S; Iliopoulos O; Kaelin W; Kerbel RS
Cancer Res; 1998 Nov; 58(21):4957-62. PubMed ID: 9810005
[TBL] [Abstract][Full Text] [Related]
38. Regulation of E2F1 by the von Hippel-Lindau tumour suppressor protein predicts survival in renal cell cancer patients.
Mans DA; Vermaat JS; Weijts BG; van Rooijen E; van Reeuwijk J; Boldt K; Daenen LG; van der Groep P; Rowland BD; Jans JJ; Roepman R; Voest EE; van Diest PJ; Verhaar MC; de Bruin A; Giles RH
J Pathol; 2013 Sep; 231(1):117-29. PubMed ID: 23744542
[TBL] [Abstract][Full Text] [Related]
39. Growth kinetics in von Hippel-Lindau-associated renal cell carcinoma.
Jilg CA; Neumann HP; Gläsker S; Schäfer O; Ardelt PU; Schwardt M; Schultze-Seemann W
Urol Int; 2012; 88(1):71-8. PubMed ID: 22156657
[TBL] [Abstract][Full Text] [Related]
40. A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma.
Suwaki N; Vanhecke E; Atkins KM; Graf M; Swabey K; Huang P; Schraml P; Moch H; Cassidy AM; Brewer D; Al-Lazikani B; Workman P; De-Bono J; Kaye SB; Larkin J; Gore ME; Sawyers CL; Nelson P; Beer TM; Geng H; Gao L; Qian DZ; Alumkal JJ; Thomas G; Thomas GV
Sci Transl Med; 2011 Jun; 3(85):85ra47. PubMed ID: 21632985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
